A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

Clinical trial NCT07268053 · RECRUITING

Trial details

NCT number: NCT07268053
Sponsor: Nader Sanai
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Glioblastoma (GBM)Brain Metastasases

Start date: 2026-02-11
Primary completion: 2027-07-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.